[Current state and key challenges of immune and cell therapy for multiple myeloma in Japan]
{{output}}
Treatment of relapsed or refractory multiple myeloma (MM) has advanced substantially with the introduction of chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibody therapy targeting B-cell maturation antigen (BCMA). CAR-T therapy induces hig... ...
